Recap: ResMed Q2 Earnings

Shares of ResMed RMD were flat in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 16.53% year over year to $1.41, which beat the estimate of $1.26.

Revenue of $800,011,000 higher by 8.67% from the same period last year, which beat the estimate of $783,180,000.

Looking Ahead

ResMed hasn't issued any earnings guidance for the time being.

ResMed hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Jan 28, 2021

Time: 04:30 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestors.resmed.com%2F&eventid=2942540&sessionid=1&key=ECFC1C693EAFA548397246F085DB9C80&regTag=&V2=false&sourcepage=register

Technicals

Company's 52-week high was at $224.43

52-week low: $108.85

Price action over last quarter: Up 12.50%

Company Profile

ResMed is one of the largest global respiratory medical devices companies, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns 65% of revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.